bebt-908
Small moleculeexperimental
Clinical trial activity
5 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Mar 2, 2016 (NCT06082596)
Timeline
Indications
Mechanism of action
PIK3C2B inhibitor
- Histone deacetylase 2INHIBITOR
HDAC2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07301138 | Phase 2 | Dec 15, 2025 | Jiao Tong University |
| NCT06792253 | Phase 3 | Jan 6, 2025 | Chinese Academy of Medical Sciences, Guangzhou BeBetter Medicine Technology Co, LTD |
| NCT06164327 | Phase 1 | Dec 1, 2023 | Chinese Academy of Medical Sciences, Guangzhou BeBetter Medicine Technology Co, LTD |
| NCT06074107 | Phase 2 | Jun 12, 2020 | Chinese Academy of Medical Sciences, Guangzhou BeBetter Medicine Technology Co, LTD |
| NCT06082596 | Phase 1 | Mar 2, 2016 | Central South University, Guangzhou BeBetter Medicine Technology Co, LTD |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Guangzhou BeBetter Medicine Technology Co, LTD | For profit | 4 | 4 | 3 | 2016 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 3 | 0 | 3 | 2020 |
| Central South University | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Jiao Tong University | Academic/Hospital | 1 | 1 | 1 | 2025 |
4 organizations
Page 1 / 1